1/ Earlier this year, our Rosetta team identified the antiporter SLC7A5 as a promising target for treating KRAS-driven pancreatic & colorectal cancers. The findings could be transformative for people whose tumours have become resistant to other trea…
RT @ABfromthelab: If you are interested in the role of LAT1-mediated metabolism in cancer, also check recent @CRUK_BI work from @malviya_gl…
RT @ABfromthelab: If you are interested in the role of LAT1-mediated metabolism in cancer, also check recent @CRUK_BI work from @malviya_gl…
RT @ABfromthelab: If you are interested in the role of LAT1-mediated metabolism in cancer, also check recent @CRUK_BI work from @malviya_gl…